Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of July 2025. The filing details a share repurchase executed on June 30, 2025, pursuant to a non-discretionary agreement with Merrill Lynch International entered into on June 4, 2025.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share buybacks. It does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics.
- Shares Purchased (June 30, 2025): 483,834 ordinary shares.
- Price Range (GBp): Lowest 1,385.50p; Highest 1,405.00p.
- Volume-Weighted Average Price (GBp): 1,397.42p.
- Trading Venue: London Stock Exchange (XLON).
- Cumulative Buyback (Since June 4, 2025): 8,038,188 ordinary shares.
- Treasury Shares Held: 226,172,571 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,089,197,628 ordinary shares.
- Treasury Voting Rights Percentage: 5.53%.
Material Changes
The filing reports a reduction in the number of shares in issue and an increase in treasury shares held by the Company. The total number of voting rights remains 4,089,197,628, which serves as the denominator for shareholder notification calculations under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or management commentary regarding operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the Company's 2024 Annual Report on Form 20-F and Q1 2025 Results.
Investor Verification Checklist
- Verify the total cumulative amount spent on the buyback program since June 4, 2025, by multiplying the cumulative share count (8,038,188) by the average price paid.
- Confirm the remaining authorization limit for the current buyback program, as the filing does not state the total program size.
- Review the 2024 Form 20-F and Q1 2025 Results referenced in the cautionary statement for detailed risk factors.
- Monitor future filings to track the progression of the treasury share percentage relative to the 5.53% reported here.